BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 2407003)

  • 1. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients.
    Schulak JA; Mayes JT; Moritz CE; Hricik DE
    Transplantation; 1990 Feb; 49(2):327-32. PubMed ID: 2407003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
    Sutherland DE; Fryd DS; Strand MH; Canafax DM; Ascher NL; Payne WD; Simmons RL; Najarian JS
    Am J Kidney Dis; 1985 Jun; 5(6):318-27. PubMed ID: 3893106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OKT3 for primary therapy of the first rejection episode in kidney transplants.
    Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM
    Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients.
    Lewis RM; Johnson PC; Golden D; Van Buren CT; Kerman RH; Kahan BD
    Transplantation; 1988 Feb; 45(2):353-9. PubMed ID: 2830686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, prospective trial of cyclosporine monotherapy versus azathioprine-prednisone from three months after renal transplantation.
    Hilbrands LB; Hoitsma AJ; Koene KA
    Transplantation; 1996 Apr; 61(7):1038-46. PubMed ID: 8623182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine toxicity: the effect of combined therapy using cyclosporine, azathioprine, and prednisone.
    Lorber MI; Flechner SM; Van Buren CT; Sorensen K; Kerman RH; Kahan BD
    Am J Kidney Dis; 1987 Jun; 9(6):476-84. PubMed ID: 3296744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation.
    Norman DJ; Kahana L; Stuart FP; Thistlethwaite JR; Shield CF; Monaco A; Dehlinger J; Wu SC; Van Horn A; Haverty TP
    Transplantation; 1993 Jan; 55(1):44-50. PubMed ID: 8420063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved results of cadaver renal transplantation with azathioprine, prednisone and antilymphoblast globulin.
    Novick AC; Khauli RB; Braun WE; Steinmuller D; Cunningham R; Buszta C; Goormastic M
    J Urol; 1984 Apr; 131(4):636-40. PubMed ID: 6368866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
    Najarian JS; Fryd DS; Strand M; Canafax DM; Ascher NL; Payne WD; Simmons RL; Sutherland DE
    Ann Surg; 1985 Feb; 201(2):142-57. PubMed ID: 3882063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants.
    Gulanikar AC; MacDonald AS; Sungurtekin U; Belitsky P
    Transplantation; 1992 Feb; 53(2):323-8. PubMed ID: 1738926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a brief steroid trial before initiating OKT3 therapy for renal allograft rejection.
    Thistlethwaite JR; Stuart JK; Mayes JT; Gaber AO; Stuart FP
    Am J Kidney Dis; 1988 Feb; 11(2):94-8. PubMed ID: 3277413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function.
    Slakey DP; Johnson CP; Callaluce RD; Browne BJ; Zhu YR; Roza AM; Adams MB
    Transplantation; 1993 Oct; 56(4):827-31. PubMed ID: 8212201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized trial of FK506-based immunosuppression after renal transplantation.
    Shapiro R; Jordan ML; Scantlebury VP; Vivas C; Fung JJ; McCauley J; Randhawa P; Demetris AJ; Irish W; Mitchell S
    Transplantation; 1995 Feb; 59(4):485-90. PubMed ID: 7533343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of delayed function on recipients of cadaver renal allografts. A study of 158 patients randomized to cyclosporine or ALG-azathioprine.
    Canafax DM; Torres A; Fryd DS; Heil JE; Strand MH; Ascher NL; Payne WD; Sutherland DE; Simmons RL; Najarian JS
    Transplantation; 1986 Feb; 41(2):177-81. PubMed ID: 3511581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OKT3 treatment of steroid-resistant renal allograft rejection.
    Thistlethwaite JR; Gaber AO; Haag BW; Aronson AJ; Broelsch CE; Stuart JK; Stuart FP
    Transplantation; 1987 Feb; 43(2):176-84. PubMed ID: 3544373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation.
    Oh CS; Stratta RJ; Fox BC; Sollinger HW; Belzer FO; Maki DG
    Transplantation; 1988 Jan; 45(1):68-73. PubMed ID: 3276066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients.
    Boudreaux JP; McHugh L; Canafax DM; Ascher N; Sutherland DE; Payne W; Simmons RL; Najarian JS; Fryd DS
    Transplantation; 1987 Sep; 44(3):376-81. PubMed ID: 3307061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing cyclosporine with antilymphoblast-globulin-azathioprine for renal allograft recipients. Results at 2 1/2-6 years.
    Johnson CP; Simmons RL; Sutherland DE; Canafax DM; Ascher NL; Payne WD; Flick B; Najarian JS; Fryd DS
    Transplantation; 1988 Feb; 45(2):380-5. PubMed ID: 3278431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.